Catalent

Biopharma leaders told McKinsey they will buy more outsourced manufacturing at higher prices

A survey of more than 300 executives has a majority planning to lean harder on contract manufacturers even as batch prices climb. McKinsey reports rising cost sensitivity and thin supplier loyalty among the same buyers.